NC CANCER TREATMENT FAIRNESS.

View NCGA Bill Details2019-2020 Session
House Bill 480 (Public) Filed Wednesday, March 27, 2019
AN ACT RELATING TO HEALTH BENEFIT PLAN COVERAGE FOR ORALLY ADMINISTERED ANTICANCER DRUGS.
Intro. by Zachary, Lewis, Lambeth.

Status: Ref To Com On Rules and Operations of the Senate (Senate action) (May 6 2019)
H 480

Bill Summaries:

  • Summary date: Mar 27 2019 - More information

    Enacts new GS 58-3-282, concerning coverage for certain anticancer drugs, applicable to every health benefit plan offered by an insurer that provides coverage for prescribed, orally administered anticancer drugs used to kill or slow the growth of cancerous cells and that provides coverage for intravenously administered or injected anticancer drugs, requiring that such plans must provide coverage for prescribed, orally administered anticancer drugs on a basis no less favorable than the coverage provided for the intravenously administered or injected anticancer drug.

    Prohibits coverage for orally administered anticancer drugs from being subject to prior authorization, dollar limit, co-payment, coinsurance, deductible provision, or any other out-of-pocket expense that does not apply to intravenously administered or injected anticancer drugs.

    Prohibits achieving compliance by reclassifying drugs or increasing cost-sharing expenses imposed on anticancer drugs. Provides that if out-of-pocket expenses are increased for anticancer drugs then the same must also be applied to the majority of comparable medical or pharmaceutical benefits of the policy, contract, or plan.

    Applies to insurance contracts issued, renewed, or amended on or after January 1, 2020.


Printer-friendly: Click to view